Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Back to dashboard
Company Information
About this company
Key people
Frank E. Thomas
Independent Chairman of the Board
Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
Timothy Keutzer
Chief Operating Officer
Milind S. Deshpande
Independent Director
Scott T. Jackson
Independent Director
John C. Pottage
Independent Director
Cynthia Smith
Independent Director
Click to see more
Key facts
- Shares in issue58.23m
- EPICSPRO
- ISINUS84833T1034
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$64.06m
- Employees25
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.